Clinical Trial Results: Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ruxolitinib before, during, and after hematopoietic stem cell transplantation in patients with primary or secondary myelofibrosis; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2026-07-09